Breaking News Instant updates and real-time market news.

ABT

Abbott

$81.82

-0.84 (-1.02%)

17:02
09/29/19
09/29
17:02
09/29/19
17:02

Abbott announces new analyses of COAPTTM Trial

Abbott announced new analyses of the landmark COAPTTM Trial that show the company's MitraClipTM device is cost effective and is projected to increase both life-expectancy and quality of life compared to guideline-directed medical therapy alone in heart failure patients with secondary mitral regurgitation (MR), or a leaky mitral heart valve. The cost-effectiveness analysis also showed additional benefits of MitraClip, including decreased use of health resources after implantation. In addition, a second late-breaking data presentation at TCT showed that over a longer-term follow-up period within the COAPT Trial, MitraClip continued to remain safe, with durable MR reduction, reduced hospitalization rates, and improved survival and quality of life compared to medical therapy alone. In tandem, the two late-breaking data sets provide strong evidence of MitraClip's impact on treating secondary MR. Significant secondary MR has historically been difficult to manage, is associated with a poor prognosis, and can lead to reduced quality of life, recurrent hospitalizations and decreased survival. The COAPT Trial cost-effectiveness analysis demonstrated: Transcatheter mitral valve repair using MitraClip in patients with significant secondary MR was projected to increase life-expectancy by 1.13 years and quality-adjusted life-years by 0.82 years. TMVr using MitraClip in patients with significant secondary MR yielded an "Incremental Cost-Effectiveness Ratio" of $55,600 per quality-adjusted life year vs GDMT. The health economic data from the COAPT Trial is the first time a pre-specified economic analysis was integrated into a pivotal randomized controlled trial that involved a mitral valve repair device. Results show that, compared with guideline directed medical therapy , TMVR using MitraClip was: Safe, provided continued reduction in MR, reduced the rate of heart failure hospitalizations; Improved survival at 36 months; Provided durable improvements in quality of life at 24 months compared to medical therapy. The three-year clinical results may further help inform a coverage review being conducted by the Centers for Medicare & Medicaid Services' for an expanded National Coverage Determination of the procedure, the company said. CMS anticipates issuing a proposed decision memo in February 2020 and will issue a final decision in May 2020.

  • 16

    Oct

ABT Abbott
$81.82

-0.84 (-1.02%)

07/18/19
BMOC
07/18/19
NO CHANGE
Target $94
BMOC
Outperform
Abbott price target raised to $94 from $87 at BMO Capital
BMO Capital analyst Joanne Wuensch raised her price target on Abbott to $94 and kept her Outperform rating after its Q2 earnings beat and a raise in FY19 guidance, saying the company is among a "handful" of medtech names that deliver above-market revenue and double-digit earnings growth along with operating leverage. The analyst notes that following its AbbVie spinoff and acquisition of St. Jude Medical and Alere, Abbott's growth drivers of Alinity, Libre and MitraClip are "humming along" - a trend she expects to continue.
07/18/19
COWN
07/18/19
NO CHANGE
Target $95
COWN
Outperform
Abbott price target raised to $95 from $86 at Cowen
Cowen analyst Joshua Jennings raised his price target on Abbott to $95 from $86 following Q2 earnings. The analyst said the quarter's highlight was the organic sales growth of 7.5% which was above its target of 7.0%, reflecting continued strength for Libre, MitraClip, and Alinity. He noted management raised it guidance for organic sales growth and earnings and he believes the company can continue to post above consensus results in the second half of the year. Jennings reiterated his Outperform rating on Abbott shares.
07/18/19
JEFF
07/18/19
NO CHANGE
Target $98
JEFF
Buy
Abbott price target raised to $98 from $80 at Jefferies
Jefferies analyst Raj Denhoy raised his price target for Abbott Laboratories to $98 from $80 saying the company's growth story is "still going strong" following its Q2 results. The quarter is more proof that the pharma exit and medtech "double-down" was right move, Denhoy tells investors in a research note. Despite Abbott's "strong" current momentum, each product cycle is still in early innings, adds the analyst. He keeps a Buy rating on the shares.
09/23/19
PIPR
09/23/19
NO CHANGE
Target $182
PIPR
Overweight
DexCom remains a 'must own' stock for investors, says Piper Jaffray
After hosting meetings with management, Piper Jaffray analyst JP McKim believes DexCom (DXCM) remains "a must own for investors." First off, the analyst does not believe the company was "walking down" numbers at a recent investor conference. Continuous glucose monitoring demand remains "robust" and importantly, G7 is only 12-15 months away, McKim tells investors in a research note. The analyst also left the meetings "with a lot more bullishness" on the hospital market as well as the non-intensive Type 2 market, where he believes DexCom's sensor technology will have an impact. McKim does expect share volatility around the near-term approval of Abbott's (ABT) Libre 2.0 with integrated continuous glucose monitoring, but he believes the impact DexCom "will be short lived in nature." McKim keeps an Overweight rating on the shares with a $182 price target. The stock closed Friday down 59c to $154.40.

TODAY'S FREE FLY STORIES

NFLX

Netflix

$286.83

2.59 (0.91%)

07:27
10/17/19
10/17
07:27
10/17/19
07:27
Recommendations
Netflix analyst commentary  »

Netflix price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Oct

AZRE

Azure Power

$12.30

(0.00%)

07:27
10/17/19
10/17
07:27
10/17/19
07:27
Initiation
Azure Power initiated  »

Azure Power initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LBTYA

Liberty Global

$26.18

0.46 (1.79%)

07:26
10/17/19
10/17
07:26
10/17/19
07:26
Downgrade
Liberty Global rating change  »

Liberty Global downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Nov

NSIT

Insight Enterprises

$57.58

0.94 (1.66%)

07:26
10/17/19
10/17
07:26
10/17/19
07:26
Recommendations
Insight Enterprises analyst commentary  »

JPMorgan…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TEUM

Pareteum

$1.02

-0.105 (-9.33%)

07:23
10/17/19
10/17
07:23
10/17/19
07:23
Downgrade
Pareteum rating change  »

Pareteum downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

CTLT

Catalent

$48.83

-0.39 (-0.79%)

07:22
10/17/19
10/17
07:22
10/17/19
07:22
Initiation
Catalent initiated  »

Catalent resumed with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Oct

  • 05

    Nov

CDEV

Centennial Resource Development

$3.42

0.09 (2.70%)

07:22
10/17/19
10/17
07:22
10/17/19
07:22
Hot Stocks
Centennial Resource Development appoints Steven Shapiro to board of directors »

Centennial Resource…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Nov

CAKE

Cheesecake Factory

$38.41

0.06 (0.16%)

07:21
10/17/19
10/17
07:21
10/17/19
07:21
Downgrade
Cheesecake Factory rating change  »

Cheesecake Factory…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Oct

  • 04

    Nov

  • 12

    Nov

NFLX

Netflix

$286.83

2.59 (0.91%)

07:20
10/17/19
10/17
07:20
10/17/19
07:20
Recommendations
Netflix analyst commentary  »

Netflix guidance adds…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Oct

AKG

Asanko Gold

$0.90

-0.0083 (-0.91%)

, GFI

Gold Fields

$5.52

0.15 (2.79%)

07:19
10/17/19
10/17
07:19
10/17/19
07:19
Hot Stocks
Asanko Gold reports Q3 AGM gold production of 62,440 ounces »

Asanko Gold (AKG)…

AKG

Asanko Gold

$0.90

-0.0083 (-0.91%)

GFI

Gold Fields

$5.52

0.15 (2.79%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NFLX

Netflix

$286.83

2.59 (0.91%)

07:17
10/17/19
10/17
07:17
10/17/19
07:17
Recommendations
Netflix analyst commentary  »

Stifel keeps Buy rating…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Oct

OLN

Olin

$18.25

-0.015 (-0.08%)

, WLK

Westlake Chemical

$62.28

-0.24 (-0.38%)

07:17
10/17/19
10/17
07:17
10/17/19
07:17
Downgrade
Olin, Westlake Chemical rating change  »

JPMorgan downgrades Olin…

OLN

Olin

$18.25

-0.015 (-0.08%)

WLK

Westlake Chemical

$62.28

-0.24 (-0.38%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Nov

  • 05

    Nov

NURO

NeuroMetrix

$0.32

-0.0249 (-7.21%)

07:15
10/17/19
10/17
07:15
10/17/19
07:15
Earnings
NeuroMetrix reports Q3 revenue $2.1M, one estimate $3.93M »

"A new commercial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

  • 12

    Nov

NFLX

Netflix

$286.83

2.59 (0.91%)

07:13
10/17/19
10/17
07:13
10/17/19
07:13
Recommendations
Netflix analyst commentary  »

Netflix's Q3…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Oct

CMA

Comerica

$65.50

-1.505 (-2.25%)

07:13
10/17/19
10/17
07:13
10/17/19
07:13
Downgrade
Comerica rating change  »

JPMorgan downgrades…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TCBI

Texas Capital

$54.33

-0.15 (-0.28%)

07:12
10/17/19
10/17
07:12
10/17/19
07:12
Recommendations
Texas Capital analyst commentary  »

Texas Capital price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PM

Philip Morris

$79.12

0.8 (1.02%)

07:11
10/17/19
10/17
07:11
10/17/19
07:11
Hot Stocks
Philip Morris backs FY19 currency-neutral net revenue growth of at least 6% »

Lowers FY19 capital…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

GOLD

Barrick Gold

$16.95

0.3 (1.80%)

07:11
10/17/19
10/17
07:11
10/17/19
07:11
Hot Stocks
Barrick Gold sees FY production towards upper end of 5.1M-5.6M ounce guidance »

Barrick Gold Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Nov

PFE

Pfizer

$36.34

-0.17 (-0.47%)

07:10
10/17/19
10/17
07:10
10/17/19
07:10
Initiation
Pfizer initiated  »

Pfizer reinstated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Oct

  • 06

    Nov

MAIN

Main Street

$42.08

0.155 (0.37%)

07:08
10/17/19
10/17
07:08
10/17/19
07:08
Earnings
Main Street declares semi-annual supplemental cash dividend of 24c in December »

Main Street declared its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Nov

POOL

Pool Corp.

$200.56

-4.63 (-2.26%)

07:08
10/17/19
10/17
07:08
10/17/19
07:08
Earnings
Pool Corp. raises FY19 EPS view $6.20-$6.40 from $6.09-$6.34 

Consensus $6.22.

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

  • 13

    Nov

PM

Philip Morris

$79.12

0.8 (1.02%)

07:08
10/17/19
10/17
07:08
10/17/19
07:08
Hot Stocks
Philip Morris revises FY19 shipment volume assumption to "down 1% - down 1.5" »

Prior guidance was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

AZN

AstraZeneca

$43.80

-0.41 (-0.93%)

07:07
10/17/19
10/17
07:07
10/17/19
07:07
Hot Stocks
AstraZeneca says trastuzumab deruxtecan granted FDA Priority Review »

AstraZeneca and Daiichi…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

  • 06

    Nov

POOL

Pool Corp.

$200.56

-4.63 (-2.26%)

07:07
10/17/19
10/17
07:07
10/17/19
07:07
Earnings
Pool Corp. reports Q3 EPS ex-items $1.84, consensus $1.78 »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

  • 13

    Nov

TXMD

TherapeuticsMD

$3.70

-0.22 (-5.61%)

07:05
10/17/19
10/17
07:05
10/17/19
07:05
Initiation
TherapeuticsMD initiated  »

TherapeuticsMD initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.